Identifai Genetics Limited (ASX:ID1) has filed its interim report covering the period 1 January 2026 to 16 July 2026, disclosing a consolidated net loss of US$2,199,792 and the completion of a Share and Option Swap Agreement that made Israeli health-technology company Identifai Genetics Ltd a wholly owned subsidiary of the Australian listed entity.
Key Points
- Consolidated loss for the period ended 16 July 2026 was US$2,199,792, compared with US$562,757 for the half-year ended 30 June 2025.
- On 16 July 2026, the Company completed the Share Swap, issuing 132,604,023 fully paid ordinary shares and 9,436,035 options with an exercise price of US$0.06, expiring 10 years from the original options' issue date.
- Identifai Israel conducted a share split on 16 July 2026, converting each existing ordinary share into 43.46 ordinary shares, resulting in 122,603,964 ordinary shares on issue prior to the swap.
- Subsequent to 16 July 2026, the Company raised A$1.5 million under a Pre-IPO seed capital raise at A$0.16 per share, with funds held as application monies at the date of the report.
- A planned prospectus public offer of 50,000,000 fully paid ordinary shares at A$0.20 per share is disclosed, targeting gross proceeds of A$10,000,000 before costs.
Share Swap Completion and Corporate Restructure on 16 July 2026
On 16 July 2026, the Company completed the acquisition of Identifai Israel pursuant to a Share and Option Swap Agreement originally entered into on 11 June 2026. Under the swap, the Company issued 132,604,023 fully paid ordinary shares on a one-for-one basis for each ordinary share held in Identifai Israel, together with 9,436,035 options exercisable at US$0.06 each and expiring 10 years from the date of issue of the original options they replaced. Prior to the swap, Identifai Israel converted all outstanding Preferred A1, Preferred A2 and Preferred A shares into ordinary shares, and 41,290 options and 18,600 warrants were exercised and converted into ordinary shares.
Lead Product Windrose™ and Intellectual Property Portfolio
The consolidated entity's lead product, Windrose™, is described in the filing as a first-trimester non-invasive prenatal test providing cfDNA-based fetal risk assessment for more than 280 clinically actionable genes from a single blood draw, without requiring a partner sample. The technology originates from more than nine years of academic and applied research at Tel Aviv University. Core intellectual property is licensed exclusively from Ramot at Tel Aviv University Ltd and is supported by a portfolio of 11 patent families, with Freedom-to-Operate clearance confirmed by independent IP counsel, according to the filing.
Pre-IPO Capital Raise and Planned Public Offer
Subsequent to 16 July 2026, the Company raised A$1.5 million under a Pre-IPO seed capital raise at an issue price of A$0.16 per share, with funds held as application monies at the date of the report. The Pre-IPO raise also includes the issue of 1,518,581 Lead Manager Pre-IPO Options at an exercise price of A$0.25 each, expiring two and a half years from the date of issue, with a total stated value of A$134,871. The planned public offer comprises 50,000,000 fully paid ordinary shares at A$0.20 per share to raise A$10,000,000 before costs, with estimated offer costs of A$1,359,690 and 10,154,970 Lead Manager Options valued at A$899,000.




Please wait processing your request...